Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients

被引：0
|
作者：
Procopio, Giuseppe
Verzoni, Elena
Iacovelli, Roberto
Testa, Isabella
Salvioni, Roberto
Nicolai, Nicola
Porcu, Luca
De Braud, Filippo G.
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Roma La Sapienza, Oncol Unit, Dept Radiol Oncol & Human Pathol, Rome, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
[4] Mario Negri Inst Pharmacol Res, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4629
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated results on long-term overall survival (OS) of the French randomized phase II trial TORAVA in metastatic renal cell carcinoma (mRCC) patients
    Bay, Jacques-Olivier
    Negrier, Sylvie
    Perol, David
    Gravis, Gwenaelle
    Chevreau, Christine
    Delva, Remy
    Blanc, Ellen
    Geoffrois, Lionnel
    Legouffe, Eric
    Ferlay, Celine
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) - a validation study
    Pond, G. R.
    Dietrich, M.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment
    Salgia, Nicholas
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
    Vano, Yann-Alexandre
    Phan, Letuan
    Simonaggio, Audrey
    Bennamoun, Mostefa
    Pannier, Diane
    Chevreau, Christine
    Borchiellini, Delphine
    Maillet, Denis
    Gross-Goupil, Marine
    Laguerre, Brigitte
    Tournigand, Christophe
    Barthelemy, Philippe
    Coquan, Elodie
    Gravis, Gwenaelle
    Sun, Cheng-Ming
    Meylan, Maxime
    Fridman, Wolf-Herve
    Sautes-Fridman, Catherine
    Elaidi, Reza
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [36] Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma
    Gu, Weijie
    Zhang, Guiming
    Sun, Lijiang
    Ma, Qi
    Cheng, Yue
    Zhang, Hailiang
    Shi, Guohai
    Zhu, Yao
    Ye, Dingwei
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2015, 6 (03) : 222 - 230
  • [37] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
    Heng, Daniel Y. C.
    Xie, Wanling
    Regan, Meredith M.
    Warren, Mark A.
    Golshayan, Ali Reza
    Sahi, Chakshu
    Eigl, Bernhard J.
    Ruether, J. Dean
    Cheng, Tina
    North, Scott
    Venner, Peter
    Knox, Jennifer J.
    Chi, Kim N.
    Kollmannsberger, Christian
    McDermott, David F.
    Oh, William K.
    Atkins, Michael B.
    Bukowski, Ronald M.
    Rini, Brian I.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5794 - 5799
  • [38] Time to surgery (TTS) in renal cell carcinoma (RCC): Predictors and association with overall survival (OS).
    Kommalapati, Anuhya
    Tella, Sri Harsha
    Tandra, Pavankumar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] A LONG-TERM SURVIVAL IN METASTATIC PAPILLARY RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPIES
    Roberto, Michela
    Bassanelli, Maria
    Giacinti, Silvana
    Poti, Giulia
    Macrini, Serena
    Aschelter, Anna Maria
    Marchetti, Paolo
    ANTICANCER RESEARCH, 2017, 37 (04) : 2087 - 2088
  • [40] OVERALL SURVIVAL DATA WITH SEQUENTIAL TARGETED THERAPIES IN METASTATIC RENAL CELL CANCER
    Procopio, Giuseppe
    Verzoni, Elena
    Iacovelli, Roberto
    Guadalupi, Valentina
    Agustoni, Francesco
    Gelsomino, Francesco
    Colonna, Valentina
    Stagni, Silvia
    Salvioni, Roberto
    ANTICANCER RESEARCH, 2011, 31 (05) : 1831 - 1831
12345